Cyber Monday saleUp to 70% OFF
Vistagen Therapeutics, Inc.Vistagen Therapeutics, Inc.Vistagen Therapeutics, Inc.

Vistagen Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

VTGN chart


Full chart

VTGN upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪79.08 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.34 USD
Net income (FY)
‪−29.36 M‬ USD
Revenue (FY)
‪1.06 M‬ USD
Shares float
‪25.02 M‬
Beta (1Y)
1.12

Employees


Employees (FY)
39
Change (1Y)
+6 +18.18%
Revenue / Employee (1Y)
‪27.28 K‬ USD
Net income / Employee (1Y)
‪−752.87 K‬ USD

About Vistagen Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Shawn K. Singh
Website
vistagen.com
Headquarters
South San Francisco
Founded
1998
FIGI
BBG000BB33L9
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

VTGN news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of VTGN is 2.84 USD — it has increased by 5.58% in the past 24 hours. Watch Vistagen Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Vistagen Therapeutics, Inc. stocks are traded under the ticker VTGN.
VTGN stock has risen by 11.81% compared to the previous week, the month change is a −6.89% fall, over the last year Vistagen Therapeutics, Inc. has showed a −24.67% decrease.
We've gathered analysts' opinions on Vistagen Therapeutics, Inc. future price: according to them, VTGN price has a max estimate of 15.00 USD and a min estimate of 12.00 USD. Watch VTGN chart and read a more detailed Vistagen Therapeutics, Inc. stock forecast: see what analysts think of Vistagen Therapeutics, Inc. and suggest that you do with its stocks.
VTGN reached its all-time high on Jan 13, 2012 with the price of 1,890.00 USD, and its all-time low was 1.62 USD and was reached on Jun 26, 2023. View more price dynamics on VTGN chart.
See other stocks reaching their highest and lowest prices.
VTGN stock is 8.45% volatile and has beta coefficient of 1.12. Track Vistagen Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Vistagen Therapeutics, Inc. there?
Today Vistagen Therapeutics, Inc. has the market capitalization of ‪79.08 M‬, it has decreased by −3.80% over the last week.
Yes, you can track Vistagen Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Vistagen Therapeutics, Inc. is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
VTGN earnings for the last quarter are −0.42 USD per share, whereas the estimation was −0.39 USD resulting in a −7.46% surprise. The estimated earnings for the next quarter are −0.51 USD per share. See more details about Vistagen Therapeutics, Inc. earnings.
Vistagen Therapeutics, Inc. revenue for the last quarter amounts to ‪183.00 K‬ USD, despite the estimated figure of ‪224.67 K‬ USD. In the next quarter, revenue is expected to reach ‪308.50 K‬ USD.
VTGN net income for the last quarter is ‪−12.96 M‬ USD, while the quarter before that showed ‪−10.73 M‬ USD of net income which accounts for −20.76% change. Track more Vistagen Therapeutics, Inc. financial stats to get the full picture.
No, VTGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 1, 2024, the company has 39.00 employees. See our rating of the largest employees — is Vistagen Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Vistagen Therapeutics, Inc. EBITDA is ‪−45.00 M‬ USD, and current EBITDA margin is ‪−3.05 K‬%. See more stats in Vistagen Therapeutics, Inc. financial statements.
Like other stocks, VTGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vistagen Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vistagen Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vistagen Therapeutics, Inc. stock shows the sell signal. See more of Vistagen Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.